Updated:
Senti Biosciences Holdings, Inc.
Senti Biosciences was founded by Timothy Lu in 2016, building a gene-circuit platform for smart cell therapies.
Senti Biosciences Holdings, Inc.
Senti Biosciences was launched in 2016 by Timothy Lu and Philip Lee, both synthetic-biology researchers from MIT and Harvard. The company's core technology — gene circuits that enable cells to sense, compute, and respond to disease microenvironments — emerged from academic work published in journals such as Nature Biotechnology (2016). Wealth origin for the founding team is not publicly disclosed, and the firm is structured as a publicly traded biotechnology company, not a family office or traditional asset manager. The firm's strategy centers on engineering logic-gated CAR-NK and CAR-T cells for oncology, targeting solid tumors through what it calls a "sense-and-respond" approach. Its lead program, SENTI-202, is in Phase 1 clinical trials for acute myeloid leukemia (AML), disclosed in a November 2024 update. Other preclinical assets address hepatocellular carcinoma (SENTI-301A) and ovarian cancer. Senti went public in February 2022 via a SPAC merger with Dynamics Special Purpose Corp., raising gross proceeds of approximately $196 million (per the firm's SEC filings). The company is headquartered in South San Francisco, with no disclosed additional offices. As of May 2026, Senti Biosciences has not disclosed total professionals count or AUM. The firm's most notable recent operational event came in November 2024, when it presented Phase 1 data for SENTI-202 at the American Society of Hematology (ASH) annual meeting, showing early signals of clinical activity in AML (per the firm's press release). No philanthropic foundation or adjacent investment vehicle has been named. The structural differentiator for Senti is its gene-circuit platform itself: rather than relying on conventional target-ligand engineering, the firm builds cells that integrate multiple environmental signals before triggering therapeutic action. This computational-biology approach — rooted in synthetic biology rather than traditional pharmacology — creates a proprietary moat around how the cells are programmed, not just what they target.
General information
Firm type
Asset Manager
Year founded
2016
AUM
Undisclosed
Location
Region
North America
Country
United States
City
South San Francisco
Corporate office
South San Francisco, California, United States
Principals
Timothy Lu
CEO and Co-founder
Philip Lee
President and Co-founder
Jim McKnight
Chief Business Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Senti Biosciences?
Investment decisions at Senti Biosciences are made by the executive team led by CEO and co-founder Timothy Lu, a synthetic-biology pioneer and MIT professor. The board of directors, which includes representatives from venture investors such as 8VC and Celgene (via a 2018 collaboration), oversees major capital allocation. No single family office or external investment committee governs the firm.
How does Senti Biosciences source its therapeutic pipeline?
Senti's pipeline originates from its proprietary gene-circuit platform, which programs cells to respond to disease-specific combinations of signals. The firm identifies new targets and circuit designs through internal research and collaborations, such as a 2018 partnership with Celgene that provided up to $100 million in milestones (per SEC filings). Academic contributions from the labs of co-founders Lu and Lee at MIT and Harvard also feed the pipeline.
Is Senti Biosciences a biotechnology company or a family office?
Senti Biosciences is a publicly traded biotechnology company, not a family office or asset manager. It was originally founded as a private venture-backed firm and went public via SPAC merger in February 2022. The firm does not manage third-party capital beyond its own corporate treasury and has no disclosed single-family-office structure.
Does Senti Biosciences participate in fund commitments or only direct therapeutic development?
Senti Biosciences engages exclusively in direct therapeutic development and does not commit capital to external funds. The firm's capital is deployed into R&D, clinical trials, and platform expansion. It has not disclosed any alternative investment activity such as venture funds, hedge funds, or private credit.
What therapeutic areas does Senti Biosciences target?
Senti Biosciences focuses on oncology, specifically solid tumors and hematologic malignancies. Its lead program, SENTI-202, targets acute myeloid leukemia (AML). Preclinical programs address hepatocellular carcinoma (SENTI-301A) and ovarian cancer. The firm's gene-circuit platform is designed to be adaptable to other disease areas, but no public disclosures exist beyond oncology.
How is Senti Biosciences funded?
Senti Biosciences was initially funded through venture capital, including a $38 million Series A in 2018 led by 8VC and Celgene (per the firm's press releases, 2018). It went public in February 2022 via a SPAC merger that raised approximately $196 million in gross proceeds (per SEC filings). No additional funding rounds or debt facilities have been publicly disclosed since the SPAC close.
Does Senti Biosciences maintain philanthropic structures?
Senti Biosciences has not publicly disclosed any philanthropic foundation or charitable arm. The firm's public filings and press materials do not reference any separate nonprofit entity or charitable giving program.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: